How to Pronounce Guillain-Barré Syndrome

Guillain-Barré syndrome is pronounced “ghee-YAN bah-RAY,” with the stress falling on the second syllable of each name. Both names are French, which is why the pronunciation trips up so many English speakers. The condition is named after two French neurologists who described it during World War I, and understanding the French roots of their names is the fastest route to getting the pronunciation right and remembering it.

Breaking Down Each Syllable

The first name, Guillain, sounds like “ghee-YAN.” The “Gu” at the start makes a hard G sound, as in “geese.” The “ill” in the middle is not pronounced like the English word “ill” but rather like the double-L in French, producing a “y” sound. The final syllable rhymes with the “on” in the French word “bon.” Put together, you get something close to “ghee-YAHN” or “ghee-YAN,” depending on how strongly you lean into the nasalized French vowel at the end.

The second name, Barré, is simpler. It sounds like “bah-RAY.” The accent mark over the final “e” (an accent aigu) tells you the last syllable is pronounced, unlike in many English words where a trailing “e” is silent. Stress falls on that second syllable. Think of it as rhyming with “ballet” but starting with a B.

The word “syndrome” is the one part English speakers already know how to say: “SIN-drohm.” So the full name, spoken at normal speed, comes out as “ghee-YAN bah-RAY SIN-drohm.” In medical settings, people often skip the full name entirely and just say “GBS,” which is universally understood among clinicians.

Common Mispronunciations and How They Happen

The most frequent mangling is “GILL-en BAR-ee,” treating both names as if they were English. This version pronounces “Guillain” to rhyme with “villain” and “Barré” as if it were the name “Barry.” You hear this constantly in news broadcasts, conversation, and even from some healthcare workers who learned the term from reading rather than hearing it.

Another common variant is “gwee-LANE bah-RAY,” where the speaker gets the French flavor of the second name right but overcorrects the first, turning the “Gu” into “Gw.” The French “Gu” before a vowel is simply a hard G, not a “Gw” blend. There is no W sound involved.

A subtler error involves the ending of “Guillain.” Some people say “ghee-LANE,” rhyming it with “lane.” The actual French pronunciation nasalizes the final vowel, so it is closer to “ghee-YAHN” with the N barely pronounced, more of a nasal resonance than a distinct consonant. If you say “ghee-YAN” cleanly, you are close enough that no one will correct you.

One reason these mispronunciations persist is that the syndrome is rare enough that most people encounter the name in print long before they ever hear it spoken. Medical students who read about it in textbooks before hearing a lecturer say it aloud sometimes carry the wrong pronunciation for years. If you have been saying it wrong, you are in large company.

Why the Name Is French

The syndrome is named after Georges Guillain and Jean Alexandre Barré, two French neurologists who, along with a third colleague named André Strohl, first described the condition in 1916. On October 13 of that year, during the Battle of the Somme, members of the Société de Neurologie serving in the French Army held a meeting where Guillain, Barré, and Strohl presented the cases of two soldiers who had developed weakness in their limbs, lost their tendon reflexes, and shown unusual spinal fluid findings.¹ Their key observation was that the soldiers’ cerebrospinal fluid had elevated protein but a normal cell count, a pattern that became a diagnostic hallmark.²

Because all three physicians were French, the eponym naturally carries French pronunciation. Medical eponyms drawn from other languages follow the same principle: Alzheimer’s is pronounced with a German “ts” sound (AHLTS-hy-mer), and Sjögren’s uses a Swedish “sh” sound (SHOW-grens). The convention is to approximate the original language, though in practice, anglicized versions dominate in English-speaking hospitals.

The Forgotten Third Name

If you look closely at the original 1916 paper, there were three authors, not two. André Strohl was the neurophysiologist who performed the electrical studies on the two soldiers’ nerves, providing critical evidence that distinguished this condition from other types of paralysis. Despite his substantial contribution, Strohl’s name was dropped from the eponym over time, and the condition became known simply as Guillain-Barré syndrome rather than Guillain-Barré-Strohl syndrome.³

The reasons for Strohl’s erasure are somewhat murky. Some historians point to the fact that Strohl was junior to Guillain and Barré and later moved away from neurology. Others note that two-name eponyms simply roll off the tongue more easily than three-name ones. Some researchers have argued that Strohl’s name deserves to be reintroduced, and you will occasionally see the full “Guillain-Barré-Strohl syndrome” in academic literature. For pronunciation purposes, Strohl would be said roughly as “STROHL,” rhyming with “roll” with a slight French softness. In everyday medical practice, though, the two-name version and the abbreviation GBS remain standard.

What the Syndrome Actually Is

Since the name comes up most often in health news and vaccine discussions, it helps to know the basics of what it refers to. Guillain-Barré syndrome is a condition in which the body’s immune system mistakenly attacks the peripheral nerves. It typically begins with tingling and weakness in the legs that can spread upward to the arms and face. In about four out of five patients, weakness starts in the lower limbs, and by the time a person seeks medical attention, all four limbs are usually affected.⁴ The hallmark features are rapidly evolving weakness, reduced or absent reflexes, and mild sensory changes.⁵

The syndrome is rare, affecting roughly one to two people per 100,000 each year. Most cases are triggered by an infection in the preceding weeks. The bacterium Campylobacter jejuni, a common cause of food poisoning, is one of the best-studied triggers. Researchers have shown that sugar molecules on the surface of this bacterium closely resemble molecules on human nerve cells. When the immune system mounts a response against the bacteria, the antibodies it produces can cross-react with the nerves, causing damage through a process called molecular mimicry.⁶ Viral infections like influenza, Epstein-Barr, and Zika have also been associated with GBS, and very rarely, certain vaccines can precede it.

Subtypes You Might Hear About

GBS is not a single disease but a family of related conditions that differ in which parts of the nerve are damaged and which nerves are targeted. The most common form in Europe and North America is acute inflammatory demyelinating polyneuropathy, or AIDP, where the immune attack strips the insulating coating (myelin) from nerve fibers. This slows or blocks the electrical signals that control muscles.⁷

In parts of Asia and Central America, axonal forms are more common, where the immune system damages the nerve fibers themselves rather than just their coating. There is also Miller Fisher syndrome, a variant that primarily affects the eyes and coordination rather than the limbs, and which involves antibodies targeting a different nerve-surface molecule.⁸ These subtypes are worth knowing about because they can look quite different from one another clinically, and a person with Miller Fisher syndrome might not recognize their symptoms from a standard description of GBS.

Diagnosis and the Signature Spinal Fluid Finding

The diagnostic clue that Guillain, Barré, and Strohl identified back in 1916 remains central to diagnosing GBS today: elevated protein in the cerebrospinal fluid without the increase in white blood cells you would expect from an infection. A lumbar puncture (spinal tap) is one of the standard tests. A systematic review pooling data from nearly 3,000 patients found that roughly 80% of GBS patients show this protein elevation when standard thresholds are used.⁹

Timing matters, though. In the first day or two after symptoms begin, only about half of patients show the abnormality. The yield rises after the first week, which means that a normal spinal tap very early in the illness does not rule out GBS. Nerve conduction studies, which measure how quickly electrical signals travel along nerves, provide additional diagnostic evidence and help classify which subtype is involved.

How GBS Is Treated

Two main treatments have been used for decades: plasma exchange (where the patient’s blood is filtered to remove the harmful antibodies) and intravenous immunoglobulin (where large doses of donated antibodies are infused to essentially overwhelm and neutralize the rogue ones). Meta-analyses comparing the two have found them to be equally effective at improving disability outcomes.¹⁰ The odds of achieving meaningful improvement are essentially the same regardless of which treatment is used.

That said, intravenous immunoglobulin tends to be more convenient to administer and has shown a slight practical advantage in reducing the need for mechanical ventilation and shortening hospital stays.¹¹ In children, plasma exchange may have a slight edge in some secondary outcomes. The choice between treatments often comes down to local hospital resources, the patient’s specific situation, and how quickly treatment can begin. Starting early matters more than which option is chosen. Steroids, which are the default treatment for many other autoimmune conditions, do not work for GBS.

Recovery and What Lingers Afterward

Most people with GBS recover substantially, though the timeline is often longer than patients expect. The acute phase, where weakness is getting worse, typically lasts two to four weeks. Recovery can take months to years, and it is frequently incomplete. Even after remyelination and nerve regrowth occur, the repaired nerve segments tend to conduct signals more slowly than they did before. Patients who had significant nerve fiber damage may achieve the ability to walk independently yet still experience early fatigue during sustained activity, neuropathic pain, and reduced exercise tolerance.¹²

Persistent immune activity and disrupted autonomic function can contribute to chronic fatigue and pain long after the acute illness resolves. This is something that often surprises survivors: they may look fine to friends and family but deal with invisible symptoms for years. Rehabilitation, including physical and occupational therapy, plays a major role in maximizing recovery. The degree of residual deficit varies enormously from person to person and depends heavily on how much axonal damage occurred during the acute phase versus how much was purely myelin-related (which tends to recover more fully).

Why Pronunciation Matters Beyond Cocktail Parties

Getting the name right is not just a matter of seeming educated. If you need to discuss this condition with a doctor, insurance company, or school administrator, mangling the pronunciation can create real confusion, especially over the phone. “GILL-en BAR-ee” may not register immediately with a clinician who knows it as “ghee-YAN bah-RAY.” Saying “GBS” sidesteps the issue entirely and is perfectly acceptable in any medical context.

For patients and their families, pronouncing the name correctly can also be a small act of self-advocacy. When you say it confidently, medical professionals tend to take your knowledge of the condition more seriously. And when you are navigating a frightening diagnosis, anything that shifts the power dynamic slightly in your favor is worthwhile. If you remember nothing else from the French pronunciation: the G is hard, the “ill” is a Y sound, and the final “é” in Barré rhymes with “ray.” That will get you close enough.

The Original 1916 Patients

The two soldiers described in the landmark 1916 presentation both developed rapidly ascending weakness and paralysis, with the legs affected before the arms. They had tingling in a “glove-and-stocking” pattern, meaning their hands and feet were most affected, and their deep tendon reflexes had vanished. Crucially, both had markedly elevated protein in their spinal fluid without the expected increase in cells.¹³ Both soldiers recovered, which is part of what distinguished this condition from polio and other causes of paralysis that were devastating troops during the war.

Guillain and Barré went on to have prominent careers in French neurology. Guillain became a professor at the Hôpital de la Salpêtrière in Paris, and Barré led the neurology department in Strasbourg. Strohl, whose electrophysiological measurements were arguably the most innovative element of the original paper, pursued a career in medical physics and faded from the neurological spotlight. The condition they described together, over a century ago in a wartime medical meeting, remains one of the most recognized neurological emergencies in the world, and its French pronunciation endures as a small daily reminder of its origins.